Table 2

Renal outcomes in the EMPA-REG OUTCOME study

Pooled empagliflozin group (n = 4,687) vs. placebo (n = 2,333)
Renal outcomeHazard ratioRelative risk reduction (%)P value
New-onset or worsening nephropathy0.61390.0001
Composite of: Doubling of serum creatinine Initiation of renal replacement therapy (includes dialysis/transplantation) Death due to renal disease0.54460.0002